Clinical trials: Lymphatic System Neoplasm
Follicular Lymphoma
Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)
The purpose of this study is to evaluate the effect of consolidation treatment Zevalin® versus maintenance treatment with Rituxan® on progression-free survival (PFS) following response induction with chemotherapy plus rituximab…
- Trial name
- NCT01662102
- Testing
- Zevalin, Rituximab
- Where
- 5 sites in United States
- Volunteers
- 1 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Lymphoma, B-cell, Diffuse
Phase I/II Study of SyB L-0501RI in Combination With Rituximab to Treat Lymphoma
For SyB L-0501RI administered by an intravenous rapid infusion in combination with rituximab, the safety will be investigated in previously untreated patients with low-grade B-cell non-Hodgkin's lymphoma (Lg-B-NHL) or mantle cell…
- Trial name
- NCT03900377
- Testing
- SyB L-0501RI
- Where
- 14 sites in Japan
- Volunteers
- 37 people
- Sponsor
- SymBio Pharmaceuticals
Pancreatic Cyst, Pancreatic Neoplasms
Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
This study focuses on four different lesions: pancreatic cysts, lymph nodes near the gastrointestinal tract, pancreatic masses and GIST tumors.
- Conditions
- Pancreatic Cyst, Pancreatic Neoplasms, Pancreatic Adenoma, Pancreatic Cancer
- Trial name
- US-nCLE (NCT01770405)
- Testing
- Endoscopic ultrasound fine needle aspiration
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Mauna Kea Technologies
Non-Hodgkin's Lymphoma
Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients
Evaluate the safety and efficacy of the dosing schedule of subcutaneous interferon gamma-1b (IFN g-1b) administered 3 times per week with Rituximab for 4 weeks, in patients with progressive or relapsed low-grade Non-Hodgkin's…
- Trial name
- NCT00057447
- Testing
- Interferon Gamma-1b, Rituximab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- InterMune
Lymphoma
Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas
An open-label, dose escalation and expansion clinical trial to evaluate the safety, tolerability and PK of HMPL-689 in patients with relapsed or refractory lymphomas
- Trial name
- NCT03786926
- Testing
- HMPL-689
- Where
- 27 sites in United States, Finland and 4 more
- Volunteers
- 53 people
- Sponsor
- Hutchmed
Multiple Myeloma
A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment
This is an open-label, multicenter clinical trial designed to evaluate the safety and potential efficacy of venetoclax and ABBV-838 combination therapy with dexamethasone in participants with relapsed or refractory multiple…
- Trial name
- NCT02951117
- Testing
- Venetoclax, ABBV-838, Dexamethasone
- Where
- 3 sites in Australia
- Sponsor
- AbbVie
Lymphocytic Leukemia, Chronic
An Observational Study on Infusion-related Adverse Events at Administration of MabThera (Rituximab) in Patients With Chronic Lymphocytic Leukemia
This observational study will monitor and register infusion-related adverse events and their handling in patients with chronic lymphocytic leukemia on treatment with MabThera (rituximab).
- Trial name
- NCT01072240
- Testing
- rituximab [Mabthera/Rituxan]
- Where
- 18 sites in Sweden
- Volunteers
- 92 people
- Sponsor
- Hoffmann-La Roche
Lymphoma
A Study of People With CD30 Positive Lymphoma in China
The main aim is to see how adult participants with newly diagnosed or relapsed/refractory CD30+ lymphoma responded to any previous treatment in China.
- Trial name
- REALM (NCT05506774)
- Where
- 11 sites in China
- Volunteers
- 1,006 people
- Sponsor
- Takeda
Lymphoma, B-Cell
A Study to Evaluate Treatment Patterns and Investigate Adult Patients With B-cell Lymphoma
This is a retrospective observational registry study designed to characterise patient profiles, assess treatment patterns, evaluate clinical outcomes and explore COO testing patterns among adult patients with newly diagnosed…
- Trial name
- Clarity-BR (NCT07882576)
- Where
- 5 sites in Brazil
- Volunteers
- 532 people
- Sponsor
- AstraZeneca
Essential Thrombocythemia
Anagrelide Retard in Essential Thrombocythemia
The purpose of this study is determine whether Anagrelide Retard is non-inferior to anagrelide immediate release form in treatment of essential thrombocythemia.
- Trial name
- TEAM-ET (NCT02076815)
- Testing
- Anagrelide retard, Thromboreductin
- Where
- 19 sites in Austria, Bulgaria and 3 more
- Volunteers
- 106 people
- Sponsor
- AOP Orphan Pharmaceuticals AG
Multiple Myeloma
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
This Phase Ib, multicenter, open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of cevostamab monotherapy, cevostamab plus pomalidomide and dexamethasone (Pd) or cevostamab…
- Trial name
- CAMMA 1 (NCT04910568)
- Testing
- Cevostamab, Tocilizumab, Pomalidomide
- Where
- 34 sites in United States, Australia and 11 more
- Volunteers
- 186 people
- Sponsor
- Genentech, Inc.
B-cell Lymphoma
A Study to Investigate Zanubrutinib in Chinese Participants With B-cell Lymphoma
This phase I clinical study was to investigate the safety, tolerability, and pharmacokinetics/pharmacodynamics of Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (BGB-3111) in Chinese participants with B-cell lymphoma by…
- Trial name
- NCT03189524
- Testing
- Zanubrutinib
- Where
- 4 sites in China
- Volunteers
- 44 people
- Sponsor
- BeiGene
B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies
This is Phase 1b/2 study to investigate the safety and effectiveness of the investigational drug, cirmtuzumab, when given in combination with ibrutinib in patients with B-cell lymphoid malignancies.
- Conditions
- B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma
- Trial name
- NCT03088878
- Testing
- Cirmtuzumab (2-16 kg/mg) plus Ibrutinib, Cirmtuzumab (300mg) plus Ibrutinib, Cirmtuzumab (600 mg) plus ibrutinib
- Where
- 12 sites in United States
- Volunteers
- 95 people
- Sponsor
- Oncternal Therapeutics, Inc
Leukemia, Lymphocytic, Chronic, B-Cell
Benefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With Chronic Lymphocytic Leukemia
The purpose of this study is to assess the impact of an individual physical activity intervention (IPAI) on health-related quality of life (HRQoL) in participants with first line or relapsed chronic lymphocytic leukemia (CLL)…
- Trial name
- QOLIBRI (NCT06299540)
- Testing
- Individual Physical Activity Intervention (IPAI), Ibrutinib
- Where
- France
- Volunteers
- 180 people
- Sponsor
- Janssen Cilag S.A.S.
Acute Lymphoblastic Leukemia, in Relapse
GRASPA (Erythrocytes Encapsulating L-asparaginase) in Patients With Relapse of Acute Lymphoblastic Leukemia
Asparaginase is a cornerstone in the treatment of ALL, but its utility is limited by toxicities including hypersensitivity. Clinical allergy is associated with inactivation of asparaginase by antibodies (A-Abs), which can also…
- Trial name
- GRASPIVOTALL (NCT01518517)
- Testing
- GRASPA, L-asparaginase
- Where
- 28 sites in Belgium, France
- Volunteers
- 85 people
- Sponsor
- ERYtech Pharma
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
The purpose of this study is to assess the safety and tolerability of zilovertamab vedotin as monotherapy and in combination in participants with select B-cell lymphomas including mantle cell lymphoma (MCL), Richter's…
- Conditions
- Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
- Trial name
- NCT05458297
- Testing
- Zilovertamab vedotin, Nemtabrutinib
- Where
- 109 sites in United States, Brazil and 19 more
- Volunteers
- 189 people
- Sponsor
- Merck Sharp & Dohme LLC
Lymphoma
RITUXIMAB BS Intravenous Infusion 100mg・500mg [Pfizer] Post-marketing Database Study
To evaluate the incidence of the outcomes for the safety specifications in patients of Medical Data Vision database in Japan diagnosed with CD20 positive B-cell non- Hodgkin's lymphoma who were treated with Rituximab Pfizer to…
- Trial name
- NCT06790420
- Testing
- Rituximab Pfizer, Rituxan
- Where
- Japan
- Volunteers
- 2,703 people
- Sponsor
- Pfizer
Advanced Solid Tumors or Lymphomas
A Phase 1 Study to Evaluate JS019 in Advanced Solid Tumors or Lymphomas
This is a phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of JS019 as monotherapy in patients with advanced malignant solid tumors/lymphomas.
- Trial name
- NCT05374226
- Testing
- JS019
- Where
- China
- Volunteers
- 172 people
- Sponsor
- Suzhou Kebo Ruijun Biotechnology Co., Ltd
Multiple Myeloma, Myeloma, Plasma-Cell
Phase I/II Study of hLL1 in Multiple Myeloma
This is a Phase I/II, open-label, multi-center study conducted in patients with recurrent or refractory multiple myeloma who have failed at least two prior standard systemic treatments.
- Conditions
- Multiple Myeloma, Myeloma, Plasma-Cell, PLASMACYTOMA
- Trial name
- NCT00421525
- Testing
- milatuzumab
- Where
- 6 sites in United States
- Volunteers
- 25 people
- Sponsor
- Gilead Sciences
Leukemia, Myelodysplastic Syndromes
3-AP and Cytarabine in Treating Patients With Hematologic Cancer
RATIONALE: Drugs used in chemotherapy such as cytarabine use different ways to stop cancer cells from dividing so they stop growing or die.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00064090
- Testing
- cytarabine, triapine
- Where
- United States
- Sponsor
- Vion Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.